Heng Mei has led a team engaging in clinical and basic
research on CAR-T and CAR-NK cell immunotherapy for a long time and has rich
basic and clinical research experience in the whole process of CAR-immune cell
product design, preparation, transfusion therapy, toxic and side effects
management, and dynamic monitoring. They have developed a series of target
heads such as CD19, CD22, BCMA, CD7, CD38, CD30, CD123, CS1, and CD7, and
innovatively constructed innovative and efficient products such as BCMA/CD38, BCMA/CS1
bispecific CAR-T, and TCR-T, and have carried out more than 20 clinical trials.
There were 412 patients with refractory recurrent blood diseases, benefiting 53
municipalities in 17 provinces across the country. Among them, the BCMA/CD38
CAR-T clinical study won the Best of ASH award in 2019, and CAR-T therapy was
successfully used to cure systemic lupus erythematosus in Central China in
2023.
Heng Mei has led a team engaging in clinical and basic
research on CAR-T and CAR-NK cell immunotherapy for a long time and has rich
basic and clinical research experience in the whole process of CAR-immune cell
product design, preparation, transfusion therapy, toxic and side effects
management, and dynamic monitoring. They have developed a series of target
heads such as CD19, CD22, BCMA, CD7, CD38, CD30, CD123, CS1, and CD7, and
innovatively constructed innovative and efficient products such as BCMA/CD38, BCMA/CS1
bispecific CAR-T, and TCR-T, and have carried out more than 20 clinical trials.
There were 412 patients with refractory recurrent blood diseases, benefiting 53
municipalities in 17 provinces across the country. Among them, the BCMA/CD38
CAR-T clinical study won the Best of ASH award in 2019, and CAR-T therapy was
successfully used to cure systemic lupus erythematosus in Central China in
2023.